Folitixorin - Isofol

Drug Profile

Folitixorin - Isofol

Alternative Names: 5-10-Methylenetetrahydrofolate; 6R-MTHF; [6R] 5,10-methylenetetrahydrofolate; ISO-901; Modufolin; Modulfolin

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Eprova
  • Developer Isofol Medical
  • Class 3-ring heterocyclic compounds; Antineoplastics; Chemoprotectants; Chemosensitisers; Folic-acids; Imidazolidines; Pyrimidinones; Small molecules; Tetrahydrofolates
  • Mechanism of Action Antimetabolites; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Colorectal cancer; Osteosarcoma
  • Phase I/II Rectal cancer

Most Recent Events

  • 12 Sep 2017 Adverse events data from a phase I/II trial in Osteosarcoma presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 04 Sep 2017 Isofol Medical plans a pivotal phase II/III ISO-CC-007 trial for Colorectal cancer (Late-stage disease, Metastatic disease, First-line therapy) in USA in the first quarter of 2018
  • 25 Aug 2017 Isofol Medical completes a phase I trial in Healthy volunteers in Sweden (NCT03203564)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top